/
Infectious Disease
Pulmonary Tuberculosis
28
Pipeline Programs↗
15
Active Trials↗
16
Companies Involved↗
Pulmonary Tuberculosis is an emerging landscape with 28 programs across 16 companies. The most active players are Otsuka, Shanghai Jiatan Pharmatech Co., Ltd. 11 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical15
Phase 1
No programs
Phase 22
Phase 311
Approved
No programs
Analysis
Trial Status
82
clinical trials
Completed48 · 59%
Unknown status15 · 18%
Recruiting10 · 12%
Not yet recruiting3 · 4%
Active, not recruiting2 · 2%
Terminated2 · 2%
Other2 · 2%
Clinical Trials
Trial Activity
82 trials
Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis
Recruiting·—·Phase 4·NCT06403943·292 enrolled
A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
Recruiting·—·Phase 3·NCT05575518·414 enrolled
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
Active, not recruiting·Centers for Disease Control and Prevention·Phase 2/3·NCT05766267·288 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)